aarkstore | 09/12/2009
MedImmune, Inc. - Strategic Analysis Review Summary MedImmune, LLC.( MedImmune), a biotechnology company focused on the development, manufacture and commercialization of medicines for the indications in Infectious Diseases, Oncology, Inflammatory Disease, cardiovascular, gastrointestinal disease and neuroscience. Its marketed products include Synagis, Ethyol, FluMist and other products. It is headquartered
Frederick County Biotech (Free subscription) | 03/23/2009
I stopped by the usual place for lunch today and was surprised to see the place full of MedImmune “regulars”. Regulars at Happy Hour, not lunch. Apparently, there was a “bomb threat” call in and they decided to evacuate the place at around 10:30-11 AM. That is just bizarre. Who’d call in a bomb threat [...]
The Boston Business Journal (Free subscription) | 03/16/2009
NKT Therapeutics, a biotechnology firm targeting so-called “Natural Killer T Cells,” has received $8 million from SV Life Sciences, a venture capital firm, and Medimmune Ventures, the venture arm of Medimmune, a subsidiary of AstraZeneca.
Fiercebiotech (Free subscription) | 03/16/2009
Nektar Therapeutics (NKT) has closed an $8 million Series A venture financing co-led by SV Life Sciences and MedImmune Ventures. NKT is at work on therapies that can selectively activate or deplete natural killer T (NKT) cells. Release
Xconomy (Free subscription) | 03/16/2009
NKT Therapeutics, a Newton, MA-based startup built around technology from Boston’s Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital, announced it has raised $8 million in a Series A financing led jointly by SV Life Sciences and MedImmune Ventures. NKT, whose website says the financing closed in December 2008, is developing [...]
Business Wire (Free subscription) | 03/16/2009
NEWTON, Mass.--(BUSINESS WIRE)--NKT Therapeutics, Inc., a privately held biotechnology company, today announced that it has closed an $8M Series A venture financing co-led by SV Life Sciences (SVLS) and MedImmune
Medical News Today (Free subscription) | 02/26/2009
A major asthma discovery by a researcher at the La Jolla Institute for Allergy and Immunology has been licensed by MedImmune, a leading innovation-focused biotechnology company and wholly owned subsidiary of AstraZeneca PLC. MedImmune licensed the discovery to explore its use in the development of a potential biologics drug for treating asthma.
Patent Baristas (Free subscription) | 02/26/2009
Earlier, the Supreme Court ruled that MedImmune could sue Genentech for patent infringement even though MedImmune continued to pay licensing fees to Genentech to use disputed technology to develop the drug Synagis®. At the same time, the U.S. Patent and Trademark Office decided to have a second review of the patents at issue, U.S. Pat. [...]
SEO News and Advices (Free subscription) | 02/23/2009
Wells Fargo, Wal-Mart, and MedImmune claim Top Honors in Excellence in Enterprise Marketing Management Indianapolis, IN ( Vocus / PRWEB ) February 23, 2009 -- Aprimo, a leading global provider of software for Enterprise Marketing Management (EMM), today announced the winners of the Aprimo Excellence (APEX) Awards. The awards were presented at the 2009 Aprimo Marketing Summit, held February 9th through...
PR News Wire (Free subscription) | 02/02/2009
Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements...
Patent Docs (Free subscription) | 01/24/2009
FX Conferences will be offering an audio conference entitled "Effective Licensing in the Wake of MedImmune v. Genentech" on January 29, 2009 from 11:30 AM to 12:30 PM (EDT). Dr. Michael Samardzija of Bracewell & Giuliani will explore the Supreme Court's decision in MedImmune v. Genentech, and the various decisions that have followed it, and provide attendees with ten drafting tips to...
The Boston Business Journal (Free subscription) | 01/16/2009
Hydra Biosciences Inc. has closed a $22.2 million Series D round of financing led by the venture capital arm of pharmaceutical giant MedImmune Inc., Hydra Biosciences said Friday.
IPBiz (Free subscription) | 01/08/2009
Of DJ, the CAFC said: In analyzing jurisdictional questions in declaratory judgment actions, there is no bright-line rule. MedImmune, 127 S. Ct. at 771. Instead, “the question in each case is whether the facts alleged, under all the circumstances, show that there is a substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance...
Business Wire (Free subscription) | 12/15/2008
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--SDI, the nation’s leading disease surveillance and healthcare informatics organization, in partnership with innovation-focused biotechnology company MedImmune, has
Fiercebiotech (Free subscription) | 12/11/2008
AstraZeneca has handed back the rights to two oncology programs it picked up in the 2007 acquisition of MedImmune. Infinity Pharmaceuticals gets the full rights to IPI-504 and IPI-493, both of which target heat shock protein 90. Researchers believe that by blocking Hsp90 they can inhibit tumor growth and promote cancer cell death. One of those programs has already advanced to late-stage testing. According...
The last article published by a user on MedImmune Inc. :
aarkstore | 09/12/2009
MedImmune, Inc. - Strategic Analysis Review Summary MedImmune, LLC.( MedImmune), a biotechnology company focused on the development, manufacture and commercialization of medicines for the indications in Infectious Diseases, Oncology, Inflammatory Disease, cardiovascular, gastrointestinal disease and neuroscience. Its marketed products include Synagis, Ethyol, FluMist and other products. It is headquartered...
Videos